Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2025 · 10-Q
Revenue$589.90K$589.90K−18.8% vs Q2 2024 Net Income-$688.70K-$688.70KN/M vs Q2 2024 EPS Diluted-$0.45-$0.45N/M vs Q2 2024 Operating Income-$724,412N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-122.8%+61.3 pt vs Q2 2024
Net margin-116.7%+58.6 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end